α-lipoic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity

被引:80
|
作者
Aguirre, N [1 ]
Barrionuevo, M [1 ]
Ramírez, MJ [1 ]
Del Río, J [1 ]
Lasheras, B [1 ]
机构
[1] Univ Navarra, Sch Med, Dept Pharmacol, Pamplona 31008, Spain
关键词
5-HT (serotonin; 5-hydroxytryptamine); glial fibrillary acidic protein (GFAP); alpha-lipoic acid (thioctic acid); 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy);
D O I
10.1097/00001756-199911260-00039
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
A single administration of 3,4-methylenedioxymethamphetamine (MDMA, 20 mg/kg, i.p.), induced significant hyperthermia in rats and reduced 5-hydroxytryptamine (5-HT) content and [H-3]paroxetine-labeled 5-HT transporter density in the frontal cortex, striatum and hippocampus by 40-60% 1 week later, MDMA treatment also increased glial fibrillary acidic protein (GFAP) immunoreactivity in the hippocampus. Repeated administration of the metabolic antioxidant alpha-lipoic acid (100 mg/kg, i.p., b.i.d. for 2 consecutive days) 30 min prior to MDMA did not prevent the acute hyperthermia induced by the drug; however, it fully prevented the serotonergic deficits and the changes in the glial response induced by MDMA. These results further support the hypothesis that free radical formation is responsible for MDMA-induced neurotoxicity. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:3675 / 3680
页数:6
相关论文
共 50 条
  • [21] Cyclophilin D is implicated in the cognitive deficits and serotonergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in mice
    Mouri, Akihiro
    Noda, Yukihiro
    Shimizu, Shigeomi
    Tsujimoto, Yoshihide
    Nabeshima, Toshitaka
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 219P - 219P
  • [22] Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: Cognitive and behavioural indices of change
    Parrott, AC
    [J]. NEUROPSYCHOBIOLOGY, 2000, 42 (01) : 17 - +
  • [23] Disruption of the discriminative stimulus effects of S(+)-3,4-methylenedioxymethamphetamine (MDMA) by (±)-MDMA neurotoxicity:: protection by fluoxetine
    Virden, TB
    Baker, LE
    [J]. BEHAVIOURAL PHARMACOLOGY, 1999, 10 (02): : 195 - 204
  • [24] The combined effects of 3,4-methylenedioxymethamphetamine (MDMA) and selected substituted methcathinones on measures of neurotoxicity
    Miner, Nicholas B.
    O'Callaghan, James P.
    Phillips, Tamara J.
    Janowsky, Aaron
    [J]. NEUROTOXICOLOGY AND TERATOLOGY, 2017, 61 : 74 - 81
  • [25] 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND OTHER AMPHETAMINE DERIVATIVES
    BOST, RO
    [J]. JOURNAL OF FORENSIC SCIENCES, 1988, 33 (02) : 576 - 587
  • [26] The Agony of Ecstasy: MDMA (3,4-Methylenedioxymethamphetamine) and the Kidney
    Campbell, Garland A.
    Rosner, Mitchell H.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (06): : 1852 - 1860
  • [27] Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans
    Freedman, RR
    Johanson, CE
    Tancer, ME
    [J]. PSYCHOPHARMACOLOGY, 2005, 183 (02) : 248 - 256
  • [28] A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy
    Sessa, Ben
    Higbed, Laurie
    Nutt, David
    [J]. FRONTIERS IN PSYCHIATRY, 2019, 10
  • [29] Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans
    Robert R. Freedman
    Chris-Ellyn Johanson
    Manuel E. Tancer
    [J]. Psychopharmacology, 2005, 183 : 248 - 256
  • [30] Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy')
    McCann, UD
    Slate, SO
    Ricaurte, GA
    [J]. DRUG SAFETY, 1996, 15 (02) : 107 - 115